In situ T cells in melanoma

[1]  J. Becker,et al.  In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. , 1999, Journal of immunology.

[2]  J. Becker,et al.  Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. , 1999, The Journal of investigative dermatology.

[3]  G. Pawelec,et al.  T cell immunosenescence in vitro and in vivo , 1999, Experimental Gerontology.

[4]  G. Pawelec,et al.  Finite lifespans of t cell clones derived from CD34+ human haematopoietic stem cells in vitro , 1999, Experimental Gerontology.

[5]  H. Pehamberger,et al.  First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites. , 1998, The Journal of investigative dermatology.

[6]  D. Mason,et al.  A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.

[7]  J. Sidney,et al.  Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. , 1998, The Journal of clinical investigation.

[8]  M. Colombo,et al.  Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. , 1998, Journal of immunology.

[9]  J. Becker,et al.  Activation of preexisting T cell clones by targeted interleukin 2 therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Möller,et al.  T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. , 1998, Journal of immunology.

[11]  A. Vallejo,et al.  Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. , 1998, Journal of immunology.

[12]  J. Zeuthen,et al.  Melanoma‐associated antigens recognized by cytotoxic T lymphocytes , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  Soldano Ferrone,et al.  Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression* , 1998, The Journal of Biological Chemistry.

[14]  R. Germain,et al.  Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. , 1998, Journal of immunology.

[15]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[16]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[17]  E. Appella,et al.  Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). , 1998, Cancer research.

[18]  C. Figdor,et al.  Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. , 1998, Journal of immunology.

[19]  C. Weyand,et al.  Functional properties of CD4+CD28− T cells in the aging immune system , 1998, Mechanisms of Ageing and Development.

[20]  B. Seliger,et al.  Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. , 1998, Cancer research.

[21]  Walker,et al.  Down‐regulation of CD28 via Fas (CD95): influence of CD28 on T‐cell apoptosis , 1998, Immunology.

[22]  T. Egeland,et al.  Demonstration of identical expanded clones within both CD8+ CD28+ and CD8+ CD28− T cell subsets in HIV type 1‐infected individuals , 1998, European journal of immunology.

[23]  J. Becker,et al.  Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[24]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[25]  L. Moretta,et al.  Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. , 1998, Immunology today.

[26]  R. Houghten,et al.  Probing degeneracy in T-cell recognition using peptide combinatorial libraries. , 1998, Immunology today.

[27]  R. Houghten,et al.  Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. , 1998, Journal of immunology.

[28]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[29]  S. Steinberg,et al.  Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.

[30]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Longo,et al.  Changes in Expression of Signal Transduction Proteins in T Lymphocytes of Patients with Leprosy , 1998, Infection and Immunity.

[32]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[33]  A. Weiss,et al.  Regulation of TCR signal transduction in murine thymocytes by multiple TCR zeta-chain signaling motifs. , 1998, Journal of immunology.

[34]  T. Mak,et al.  Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. , 1997, Immunity.

[35]  G. Pawelec,et al.  Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? , 1997, Immunology today.

[36]  D. Hicklin,et al.  β2-Microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance , 1997, Melanoma research.

[37]  B. Giannotti,et al.  In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. , 1997, Melanoma research.

[38]  P. Walker,et al.  TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture. , 1997, International immunology.

[39]  A. Weiss,et al.  CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites , 1997, Molecular and cellular biology.

[40]  G. Halliday,et al.  T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. , 1997, The Journal of investigative dermatology.

[41]  G. Carcelain,et al.  Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. , 1997, Journal of immunology.

[42]  J. Zeuthen,et al.  Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines , 1997, International journal of cancer.

[43]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[44]  S. Matsushita,et al.  Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. , 1996, Journal of immunology.

[45]  J. Ceuppens,et al.  CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model , 1996, Immunological reviews.

[46]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[47]  C. Weyand,et al.  The Repertoire of CD4+ CD28− T Cells in Rheumatoid Arthritis , 1996, Molecular medicine.

[48]  F. Marincola,et al.  Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) , 1996, The Journal of experimental medicine.

[49]  J. Becker,et al.  Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. , 1996, The Journal of clinical investigation.

[50]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[51]  Alexey M. Olovnikov,et al.  Telomeres, telomerase, and aging: Origin of the theory , 1996, Experimental Gerontology.

[52]  C. Harley,et al.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. , 1996, AIDS.

[53]  P. Moss,et al.  Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. , 1996, Blood.

[54]  Michael Loran Dustin,et al.  Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area , 1996, The Journal of cell biology.

[55]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[56]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[57]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[58]  G. Parmiani,et al.  Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. , 1995, Immunology today.

[59]  D. Longo,et al.  Alterations in T cell receptor and signal transduction molecules in melanoma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  P. Romero,et al.  Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1 , 1995, The Journal of experimental medicine.

[61]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[62]  G. Pawelec,et al.  Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? , 1995, Mechanisms of Ageing and Development.

[63]  A. Anichini,et al.  Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. , 1995, Cancer research.

[64]  P. Itin,et al.  In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. , 1995, Carcinogenesis.

[65]  M. Matsuda,et al.  Alterations in the signal‐transducing molecules of T cells and nk cells in colorectal tumor‐infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease , 1995, International journal of cancer.

[66]  A. McLean,et al.  In vivo estimates of division and death rates of human T lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Kourilsky,et al.  T-cell repertoire diversity and clonal expansions in normal and clinical samples. , 1995, Immunology today.

[68]  X. Sastre,et al.  Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.

[69]  L. Samelson,et al.  Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists , 1995, Science.

[70]  C. Garbe,et al.  Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. , 1994, Anticancer research.

[71]  S. Rosenberg,et al.  Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. , 1994, Cancer research.

[72]  J. Becker,et al.  Maintenance of clonal anergy by endogenously produced IL-10. , 1994, International immunology.

[73]  P. Kourilsky,et al.  Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. , 1994, Journal of immunology.

[74]  S. Narula,et al.  Stimulation of Cytolytic Activity by Interleukin‐10 , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[75]  G. Carcelain,et al.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.

[76]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[77]  P. Hersey,et al.  Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma , 1994, International journal of cancer.

[78]  J. Becker,et al.  Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. , 1993, International immunology.

[79]  G. Carcelain,et al.  Evidence for in situ amplification of tumor-specific cytotoxic T lymphocytes in a human regressive melanoma , 1993 .

[80]  S. Ferrone,et al.  Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. , 1993, Cancer research.

[81]  M. Lotze,et al.  Usage of T‐cell receptor Vβ chain genes in fresh and cultured tumor‐infiltrating lymphocytes from human melanoma , 1993 .

[82]  A. Mackensen,et al.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.

[83]  K. Keyomarsi,et al.  Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. , 1992, Cancer research.

[84]  G. Nicolini,et al.  Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[85]  W. Clark.  Tumour progression and the nature of cancer. , 1991, British journal of cancer.

[86]  D. Ruiter,et al.  MHC antigens in human melanomas. , 1991, Seminars in cancer biology.

[87]  L. Steinman,et al.  Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. , 1990, Science.

[88]  A. Begovich,et al.  Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients , 1990, Nature.

[89]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[90]  L. Hayflick.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[91]  S. Rosenberg,et al.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand. , 1999, Cancer research.

[92]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[93]  F. Marincola,et al.  Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. , 1998, Critical reviews in immunology.

[94]  A. Roberts,et al.  Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.

[95]  P. Kourilsky,et al.  Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. , 1998, Critical reviews in immunology.

[96]  P. Guldberg,et al.  Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). , 1998, BioTechniques.

[97]  Gideon Berke,et al.  Killing mechanisms of cytotoxic lymphocytes , 1997, Current opinion in hematology.

[98]  R. Perlmutter,et al.  Differential signaling by lymphocyte antigen receptors. , 1997, Annual review of immunology.

[99]  G. Pawelec,et al.  Escape from host-antitumor immunity. , 1997, Critical reviews in oncogenesis.

[100]  K. Miyazono,et al.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins. , 1997, Nature.

[101]  D. Avidandrews,et al.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites , 1997 .

[102]  S. Rosenberg,et al.  T-cell recognition of self peptides as tumor rejection antigens , 1996, Immunologic research.

[103]  J. Schøller,et al.  Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. , 1994, Cancer immunology, immunotherapy : CII.

[104]  J. Schøller,et al.  Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. , 1994, International journal of cancer.

[105]  S. Roman-Roman,et al.  Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. , 1992, Cancer research.

[106]  M. Davis,et al.  T cell receptor gene diversity and selection. , 1990, Annual review of biochemistry.

[107]  T. Mak,et al.  Thymic ontogeny and selection of alpha beta and gamma delta T cells. , 1989, Immunology today.

[108]  S. Rosenberg.  Immunotherapy of cancer using interleukin 2: current status and future prospects. , 1988, Immunology today.

[109]  R. Myers,et al.  Detection and localization of single base changes by denaturing gradient gel electrophoresis. , 1987, Methods in enzymology.

[110]  T. Mitsudomi,et al.  E-mail alerts Sign up to receive free email-alerts related to this article or journal. Reprints and Subscriptions Permissions , 1947 .